Pharmaceutical composition for preventing or treating angiogenesis-related diseases

A pharmaceutical composition using 1-(cyclobutylcarbonyl)-3-(4-chlorophenyl)urea inhibits cell migration and angiogenesis, addressing the inadequacies of current treatments for angiogenesis-related diseases by reducing fibrous scar formation and preserving retinal function.

JP7580123B2Active Publication Date: 2024-11-11YAMAGUCHI UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2021542934
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-08-25
Filing Date
2020-08-25
Publication Date
2024-11-11
Estimated Expiration
2040-08-25

AI Technical Summary

Technical Problem

Current treatments for angiogenesis-related diseases, such as diabetic retinopathy and age-related macular degeneration, are inadequate in preventing neovascularization recurrence and associated complications like fibrous scar formation, leading to poor visual outcomes and organ dysfunction.

Method used

A pharmaceutical composition containing 1-(cyclobutylcarbonyl)-3-(4-chlorophenyl)urea or its pharmacologically acceptable salts is developed to inhibit cell migration, epithelial-to-mesenchymal transition, and angiogenesis, thereby suppressing fibrotic scar formation and neovascularization in the retina and other tissues.

Benefits of technology

The composition effectively inhibits cell migration and fibrosis, reducing fibrous scar formation and angiogenesis, thereby preserving retinal function and preventing organ dysfunction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007580123000002
    Figure 0007580123000002
  • Figure 0007580123000003
    Figure 0007580123000003
  • Figure 0007580123000004
    Figure 0007580123000004
Patent Text Reader

Abstract

The present invention addresses the problem of providing a novel medicine that is effective for preventing or treating angiogenesis-related diseases. As a means for solving the problem, produced is a medicinal composition that comprises, as an active ingredient, 1-(cyclobutylcarbonyl)-3-(4-chlorophenyl)urea or a pharmacologically acceptable salt thereof. Preferably, the medicinal composition is used for preventing or treating angiogenesis-related diseases. Preferably, the angiogenesis-related diseases are ophthalmic angiogenesis-related diseases. Preferably, the ophthalmic angiogenesis-related diseases concern to the formation or constriction of fibrous scars in epiretinal, intraretinal and / or subretinal tissues.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a pharmaceutical composition comprising 1-(cyclobutylcarbonyl)-3-(4-chlorophenyl)urea or a pharmacologically acceptable salt thereof as an active ingredient. [Background technology]

[0002] In Japan, where the population is aging, it is believed that the proportion of retinal and choroidal disorders such as diabetic retinopathy, retinal detachment, and age-related macular degeneration will continue to increase as a cause of blindness. The prognosis of these diseases, which previously caused blindness, is improving due to the development of vitreous surgery and the introduction of biological drugs such as anti-VEGF intraocular injections that suppress neovascularization. However, the prognosis of visual function in severe cases, such as those that have been left untreated for a long time or have recurred, is still poor, leaving aside early cases. In addition, even with the use of anti-VEGF intraocular injections, the problem of recurrence and prolongation of intraocular neovascularization cannot be avoided. Neovascularization is fragile and prone to rupture, and blood or components in the blood may leak into the surrounding tissues. Such leakage of blood or components in the blood into the surrounding tissues can cause inflammation, and scarring associated with inflammation can be formed, which can eventually destroy the cells of the surrounding tissues and cause various diseases.

[0003] Even if the retina is reattached by surgery, if the retina cells have already suffered irreversible secondary damage, the photoreceptor function will decline. Even if the wound heals, the eye is an organ that is completely meaningless if visual function is lost. In order to preserve retinal function, it is important to suppress neovascularization of the retina and choroid or ocular inflammation with as little damage as possible, and to control the secondary reactions that follow.

[0004] It has been reported that the formation or rupture of retinal-choroidal neovascularization involves the proliferation of vascular endothelial cells, enhanced lumen formation, etc. Furthermore, it has been reported that retinal pigment epithelial cells are involved as a representative cellular component that constitutes retinal fibrous scars. In advanced retinal-choroidal disorders, the epithelial-mesenchymal transition (EMT) of retinal pigment epithelial cells is promoted, leading to scar formation and contraction, resulting in retinal dysfunction. Therefore, it is believed that inhibiting the epithelial-mesenchymal transition of retinal pigment epithelial cells, the proliferation of vascular endothelial cells, or enhanced lumen formation is effective against diseases such as retinal-choroidal disorders.

[0005] The present inventors have been conducting research into inhibitors of retinal and choroidal disorders, and have disclosed, for example, an inhibitor of retinal and choroidal disorders containing, as an active ingredient, (E)-4-(2-{3-[(1H-pyrazol-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl}vinyl)benzoic acid, its ester, or a salt thereof (see Patent Document 1).

[0006] Meanwhile, in recent years, it has been revealed that compounds having an acylphenylurea structure as a basic skeleton inhibit melanoma motility (see Non-Patent Document 1). However, the relationship between compounds having an acylphenylurea structure as a basic skeleton and retinal choroidal disorder or EMT is unknown. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] International Publication No. 2014 / 188716 Brochure [Non-patent literature]

[0008] [Non-Patent Document 1] Kyoto University Education and Research Promotion Foundation Grant Project "Elucidation of the mechanism of action of a new low-molecular compound that inhibits cell motility and its application to cancer treatment" Results report Bunta Watanabe (Kyoto University Education and Research Promotion Foundation website http: / / www.kyodai-zaidan.or.jp / system / wp-content / uploads / 2017 / 03 / seika_29_1-watanabe-bunta.pdf) Summary of the Invention [Problem to be solved by the invention]

[0009] An object of the present invention is to provide a pharmaceutical composition that is effective for preventing or treating angiogenesis-related diseases. [Means for solving the problem]

[0010] Searching for drugs effective against angiogenesis-related diseases, particularly retinal and choroidal disorders, is an important and interesting subject in the field of ophthalmology. The present inventors conducted intensive research to search for new drugs effective against retinal and choroidal disorders, and found that 1-(cyclobutylcarbonyl)-3-(4-chlorophenyl)urea or a pharmacologically acceptable salt thereof exhibited inhibitory effects on cell migration and epithelial-mesenchymal transition in pharmacological tests using human retinal pigment epithelial cells, and further suppressed fibrotic scar formation in a mouse retinal fibrosis model. Furthermore, the inventors found that the above-mentioned 1-(cyclobutylcarbonyl)-3-(4-chlorophenyl)urea inhibited angiogenesis and suppressed the expression of fibrosis markers not only in retinal cells but also in lung and liver cells, and thus completed the present invention.

[0011] That is, the present invention is as follows. [1] A pharmaceutical composition comprising 1-(cyclobutylcarbonyl)-3-(4-chlorophenyl)urea or a pharmacologically acceptable salt thereof as an active ingredient. [2] The pharmaceutical composition according to [1] above, which is used for the prevention or treatment of angiogenesis-related diseases. [3] The pharmaceutical composition according to [2] above, wherein the angiogenesis-associated disease is an ocular angiogenesis-associated disease. [4] The pharmaceutical composition according to [3] above, wherein the ocular angiogenesis-related disease is retinal-choroidal disorder, keratoconjunctival disorder, or neovascular glaucoma. [5] The pharmaceutical composition according to [4] above, wherein the retinal and choroidal disorders are diabetic retinopathy, age-related macular degeneration, retinal detachment, proliferative vitreoretinopathy, uveitis, eye infection, retinopathy of prematurity, neovascular maculopathy or retinal and choroidal inflammation. [6] The pharmaceutical composition according to [3] above, characterized in that the ocular angiogenesis-related disease is the formation or contraction of fibrous scars caused by any one of retinal-choroidal disorders, keratoconjunctival disorders, and neovascular glaucoma. [7] The pharmaceutical composition according to [6] above, characterized in that the fibrotic scar is epiretinal, intraretinal and / or subretinal fibrotic scar. [8] The pharmaceutical composition according to [7] above, wherein the fibrous scar is a fibrous scar in the retinal pigment epithelium tissue under the retina. [9] The pharmaceutical composition according to [3] above, wherein the angiogenesis-related disease is organ fibrosis.

[10] The pharmaceutical composition according to [9] above, wherein the organ fibrosis is pulmonary fibrosis or liver fibrosis.

[11] The pharmaceutical composition according to [1] above, which is used for inhibiting angiogenesis.

[12] The pharmaceutical composition according to

[11] above, wherein the angiogenesis is ocular angiogenesis.

[13] The pharmaceutical composition according to

[12] above, wherein the angiogenesis is epiretinal, intraretinal and / or subretinal angiogenesis.

[0012] Further, other aspects of the present invention are as follows. (1) 1-(cyclobutylcarbonyl)-3-(4-chlorophenyl)urea, or a pharmacologically acceptable salt thereof, for use in the prevention or treatment of angiogenesis-related diseases. (2) A method for preventing or treating angiogenesis-related diseases, comprising administering to a subject in need thereof an effective amount of 1-(cyclobutylcarbonyl)-3-(4-chlorophenyl)urea or a pharmacologically acceptable salt thereof. (3) Use of 1-(cyclobutylcarbonyl)-3-(4-chlorophenyl)urea or a pharmacologically acceptable salt thereof for preparing a pharmaceutical composition for use in the prevention or treatment of angiogenesis-associated diseases. (4) 1-(cyclobutylcarbonyl)-3-(4-chlorophenyl)urea, or a pharmacologically acceptable salt thereof, for use in inhibiting angiogenesis. (5) A method for inhibiting angiogenesis, which comprises administering to a subject in need thereof an effective amount of 1-(cyclobutylcarbonyl)-3-(4-chlorophenyl)urea or a pharmacologically acceptable salt thereof. (6) Use of 1-(cyclobutylcarbonyl)-3-(4-chlorophenyl)urea or a pharmacologically acceptable salt thereof for preparing a pharmaceutical composition for use in inhibiting angiogenesis. Effect of the Invention

[0013] According to the present invention, it is possible to provide a pharmaceutical composition that exhibits excellent effects in preventing or treating angiogenesis-related diseases and suppressing angiogenesis. [Brief description of the drawings]

[0014] [Figure 1] FIG. 1 shows the results of measuring the width of the wound on the culture bottom after 18 hours of culture with the addition of DMEM containing 0.3% FBS (control), or DMEM containing 0.3% FBS+BPU17 (1, 3, or 5 μM) in Example 1. [Diagram 2] FIG. 2 shows photographs of the culture bottom after 0 hour or 18 hours of culture treatment with DMEM containing 0.3% FBS (control) or 3 μM BPU17 in Example 1. [Diagram 3] FIG. 1 shows the results of observing cells under a fluorescence microscope in Example 2. [Figure 4]FIG. 1 shows the results of immunoblotting in Example 2. [Diagram 5] FIG. 13 shows the results of enucleating an eyeball and observing it under a microscope in Example 3. [Figure 6] FIG. 13 shows the results of measuring the fibrosis area of ​​the enucleated eyeball in Example 3. [Figure 7] 1 shows the results of investigating the BrdU incorporation rate in aortic vascular endothelial cells in Example 4. [Figure 8] FIG. 13 is a photograph taken under a microscope (×40) 22 hours after inoculation of the HAoEC solution in Example 5. [Figure 9A] FIG. 13 is a diagram showing the percentage (%) of branching points per cell number 22 hours after inoculation of an HAoEC solution in Example 5. [Figure 9B] FIG. 13 shows the tube length (μm) 22 hours after inoculation with a HAoEC solution in Example 5. [Figure 10] FIG. 13 shows the results of enucleating the eyeball and observing it under a microscope in Example 6. [Figure 11] FIG. 13 is a diagram showing the measurement results of the area of ​​chorioretinal neovascularization (CNV) in the enucleated eyeball in Example 6. [Figure 12] FIG. 13 shows the results of measuring the expression level of CTGF mRNA in Example 7. [Figure 13] FIG. 13 shows the results of measuring the expression level of αSM-actin mRNA in Example 7. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] The pharmaceutical composition in this specification is not particularly limited as long as it contains, as an active ingredient, 1-(cyclobutylcarbonyl)-3-(4-chlorophenyl)urea (hereinafter also referred to as "the compound" or "BRU17") represented by the following formula (I), or a pharmacologically acceptable salt thereof (hereinafter also referred to as "the pharmaceutical composition"), but is preferably used for the prevention or treatment of angiogenesis-related diseases or for the inhibition of angiogenesis.

[0016] [ka]

[0017] The above-mentioned "angiogenesis-associated disease" in the present specification may include ocular angiogenesis-associated disease or organ fibrosis. Such "ocular angiogenesis-associated disease" may include angiogenesis-associated disease in the retina, choroid, cornea, conjunctiva, sclera, uvea, vitreous body, or lens, such as retinal choroidal disorder, keratoconjunctival disorder, and neovascular glaucoma. The retinal choroid refers to the combined tissue of the retina and choroid.

[0018] The above-mentioned "retinal choroidal disorder" in this specification means a state in which damage occurs to photoreceptor cells, ganglion cells, retinal pigment epithelial cells, and tissues composed of the above-mentioned cells in the retina and / or choroid, which may ultimately lead to cell death or tissue dysfunction, resulting in abnormalities in visual functions such as visual acuity and visual field. Specific examples include diabetic retinopathy, age-related macular degeneration, retinal detachment, proliferative vitreoretinopathy, uveitis, eye infection, retinopathy of prematurity, neovascular maculopathy, retinal choroiditis, retinal and / or choroidal neovascularization, and retinal and / or subretinal hemorrhage secondary to the formation of retinal and / or choroidal neovascularization.

[0019] The above-mentioned "corneal and conjunctival disorders" in this specification refers to the state in which corneal epithelium, corneal stroma, and corneal endothelium are damaged.Specific examples include keratitis, corneal trauma, corneal ulcer, corneal epithelial peeling, dry eye, corneal erosion, corneal transplant rejection, corneal erosion, persistent corneal disorder, superficial punctate keratopathy, corneal epithelial defect, corneal neovascularization, conjunctivitis, conjunctival ulcer, conjunctival epithelial defect, and conjunctival neovascularization.

[0020] The term "fibrous scar" as used herein refers to fibrous connective tissue formed at the site of injury of inflammatory tissue with the subsidence or progression of inflammation due to bleeding, surgery, infection, etc. The term "fibrous scar formation" refers to the formation of fibrous connective tissue at the site of injury with the subsidence or progression of inflammation, and the term "fibrous scar contraction" refers to the contraction of the tissue surrounding the fibrous scar by attracting it when the formed fibrous scar heals. The formation and contraction of fibrous scar occur in a series, and by inhibiting the formation and contraction of this fibrous scar, it is possible to prevent the deformation of the tissue surrounding the fibrous scar, which causes the impairment of the function of ocular tissue.

[0021] The fibrous scar may be caused by any one of the following: retinal choroidal disorder, keratoconjunctival disorder, and neovascular glaucoma. The site where the fibrous scar is formed or contracted may be anywhere in the eye, and examples of the fibrous scar include epiretinal, intraretinal, and / or subretinal fibrous scar, corneal fibrous scar, and conjunctival fibrous scar, and preferably retinal pigment epithelial fibrous scar under the retina. The above-mentioned "epiretinal" refers to the area above the retinal surface, and the above-mentioned "subretinal" refers to the area between the retina and the choroid, the area within the choroid, and the area under the choroid.

[0022] The above-mentioned "fibrous scar on the retina, in the retina, and / or under the retina" refers to fibrous connective tissue generated at the damaged site on the retina, in the retina, and / or under the retina, preferably at the damaged site under the retina, as the ocular inflammation subsides or progresses, and is a tissue mainly composed of retinal pigment epithelial cells, fibroblasts, glial cells, etc. and extracellular matrix such as collagen. The formation and contraction of such fibrous scar on the retina, in the retina, and / or under the retina occurs in a series, and by inhibiting the formation and contraction of this fibrous scar, it is possible to prevent the deformation of the macular part of the fibrous scar on the retina, in the retina, and / or under the retina and the surrounding tissues, which causes impairment of the retinal choroidal function.

[0023] The above-mentioned "organ fibrosis" in this specification refers to fibrosis in one process of wound healing of an injured organ, in which the balance between inflammation and production and decomposition of extracellular matrix is ​​lost, leading to a persistent excessive state (chronic inflammation) and causing hardening changes in the organ, and such organ fibrosis leads to organ dysfunction and ultimately organ failure. Examples of the organ fibrosis include pulmonary fibrosis, liver fibrosis, kidney fibrosis, pancreatic fibrosis, myocardial fibrosis, digestive tract fibrosis, bone marrow fibrosis, and postoperative scarring.

[0024] The angiogenesis in the above-mentioned "inhibition of angiogenesis" in this specification is not particularly limited, but preferably includes angiogenesis in the eye, preferably epiretinal, intraretinal and / or subretinal, corneal, or conjunctival angiogenesis. In addition, inhibition of angiogenesis means inhibition of the formation or growth of new blood vessels from existing blood vessels.

[0025] The compound of the present invention or a salt thereof, which is an active ingredient of the pharmaceutical composition of the present invention, can be obtained by an organic synthesis method using a known organic chemical reaction, such as the method described in Non-Patent Document 1 above, or can be purchased as a commercially available product.

[0026] Suitable examples of the above-mentioned "pharmacologically acceptable salts" include: (1) acid addition salts, such as inorganic acid salts such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, and phosphate; or organic acid salts such as acetate, trifluoroacetate, benzoate, oxalate, malonate, succinate, maleate, fumarate, tartrate, citrate, methanesulfonate, ethanesulfonate, trifluoromethanesulfonate, benzenesulfonate, p-toluenesulfonate, glutamate, and aspartate; or (2) basic salts, such as metal salts such as sodium salt, potassium salt, calcium salt, and magnesium salt; inorganic salts such as ammonium salt; or organic amine salts such as triethylamine salt and guanidine salt.

[0027] The pharmaceutical composition of the present invention can be mixed with appropriate pharmacologically acceptable additives and administered as an eye drop preparation. It can be formulated by a known method by appropriately blending additives such as isotonicity agents, buffers, pH regulators, solubilizers, thickeners, stabilizers, and preservatives (antiseptics). It is also possible to obtain a stable eye drop preparation by adding a pH regulator, thickener, dispersant, and the like to suspend the drug.

[0028] Examples of the isotonic agent include glycerin, propylene glycol, sodium chloride, potassium chloride, sorbitol, and mannitol.

[0029] Examples of the buffer include phosphoric acid, phosphates, citric acid, acetic acid, and ε-aminocaproic acid.

[0030] Examples of the pH adjuster include hydrochloric acid, citric acid, phosphoric acid, acetic acid, sodium hydroxide, potassium hydroxide, boric acid, borax, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium carbonate, and sodium hydrogen carbonate.

[0031] Examples of the solubilizing agent include polysorbate 80, polyoxyethylene hydrogenated castor oil 60, macrogol 4000, and the like.

[0032] Examples of the thickener and dispersant include cellulose polymers such as hydroxypropylmethylcellulose and hydroxypropylcellulose; polyvinyl alcohol; and polyvinylpyrrolidone. Examples of the stabilizer include edetic acid and sodium edetate.

[0033] Examples of the preservatives (antiseptics) include commonly used sorbic acid, potassium sorbate, benzalkonium chloride, benzethonium chloride, methyl parahydroxybenzoate, propyl parahydroxybenzoate, chlorobutanol, etc., and these preservatives can also be used in combination.

[0034] The pH of the eye drops may be within the range acceptable for ophthalmic preparations, and is preferably set to 4.0 to 8.5.

[0035] In addition to the above-mentioned eye drop type, the pharmaceutical composition of the present invention can be administered orally or parenterally (intravenously, intramuscularly, intraperitoneally, transdermally, transtracheally, intradermally or subcutaneously) in the form of ointments (preferably eye ointments), injections, tablets, granules, fine granules, powders, capsules, inhalants, syrups, pills, liquids, suspensions, emulsions, transdermal agents, suppositories, lotions, etc., which are prepared by mixing with appropriate pharmacologically acceptable additives. These preparations are prepared by well-known methods using additives such as excipients, lubricants, binders, disintegrants, emulsifiers, stabilizers, flavorings, or diluents.

[0036] The above-mentioned excipients include, for example, organic excipients and inorganic excipients. Examples of organic excipients include sugar derivatives such as lactose, sucrose, glucose, mannitol, and sorbitol; starch derivatives such as corn starch, potato starch, α-starch, and dextrin; cellulose derivatives such as crystalline cellulose; gum arabic; dextran; and pullulan. Examples of inorganic excipients include light anhydrous silicic acid; and sulfates such as calcium sulfate.

[0037] Examples of the lubricants include stearic acid; metal stearates such as calcium stearate or magnesium stearate; talc; colloidal silica; waxes such as beeswax or glomerulus; boric acid; adipic acid; sulfates such as sodium sulfate; glycol; fumaric acid; sodium benzoate; D,L-leucine; sodium lauryl sulfate; silicic acids such as silicic anhydride or silicic acid hydrate; or starch derivatives among the above excipients.

[0038] Examples of the binder include hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinylpyrrolidone, macrogol, and the compounds listed above as excipients.

[0039] Examples of the disintegrant include cellulose derivatives such as low-substituted hydroxypropylcellulose, carboxymethylcellulose, carboxymethylcellulose calcium, and internally crosslinked carboxymethylcellulose calcium; crosslinked polyvinylpyrrolidone; and chemically modified starches or cellulose derivatives such as carboxymethylstarch and carboxymethylstarch sodium.

[0040] Examples of the emulsifier include colloidal clays such as bentonite or veegum; anionic surfactants such as sodium lauryl sulfate; cationic surfactants such as benzalkonium chloride; and nonionic surfactants such as polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters, and sucrose fatty acid esters.

[0041] Examples of the stabilizer include parahydroxybenzoic acid esters such as methylparaben or propylparaben; alcohols such as chlorobutanol, benzyl alcohol or phenylethyl alcohol; benzalkonium chloride; phenols such as phenol or cresol; thimerosal; acetic anhydride; or sorbic acid.

[0042] Examples of the flavoring agent include sweeteners such as saccharin sodium or aspartame; acidulants such as citric acid, malic acid or tartaric acid; and flavorings such as menthol, lemon extract or orange extract.

[0043] The diluents are compounds that are commonly used as diluents, such as lactose, mannitol, glucose, sucrose, calcium sulfate, hydroxypropyl cellulose, microcrystalline cellulose, water, ethanol, polyethylene glycol, propylene glycol, glycerol, starch, polyvinylpyrrolidone, or mixtures thereof.

[0044] The above ointment (preferably an eye ointment) can be prepared using a commonly used base such as white petrolatum or liquid paraffin.

[0045] The dosage of the pharmaceutical composition of the present invention can be appropriately changed depending on the dosage form, the severity of the symptoms of the patient to be administered, the age, the body weight, the doctor's judgment, etc., but in the case of eye drops, the active ingredient concentration is 0.000001 to 10% (W / V), preferably 0.00001 to 3% (W / V), more preferably 0.0001 to 1% (W / V), which can be administered once or several times a day, and in the case of oral preparations, generally, 0.01 to 5000 mg, preferably 0.1 to 2500 mg, more preferably 0.5 to 1000 mg per day for adults, which can be administered once or several times. In addition, in the case of eye ointments, the active ingredient concentration is 0.00001 to 10% (W / W), preferably 0.0001 to 3% (W / W), more preferably 0.001 to 1% (W / W), which can be administered once or several times a day.

[0046] As used herein, the term "prevention" refers to a measure aimed at suppressing or preventing the onset and recurrence of diseases associated with loss, functional disorder, or dysfunction of cells, tissues, or organs.

[0047] As used herein, "treatment" refers to a measure aimed at slowing or stopping the progression or aggravation of a disease associated with a defect and functional disorder or dysfunction of a cell, tissue or organ, and at alleviating, improving or curing a disease associated with a defect and functional disorder or dysfunction of a cell, tissue or organ.

[0048] The present invention will be described in more detail below with reference to examples, but the technical scope of the present invention is not limited to these examples.

[0049] [Example 1] To investigate the effect of BPU17 on the prevention or treatment of retinal-choroidal disorders, the following experiment was performed using human retinal pigment epithelial cells RPE-1. Note that retinal pigment epithelial cells are a typical cell component that forms fibrous scars in the retina. Human retinal pigment epithelial cells RPE-1 were cultured in 10% FBS medium. The cultured cells were seeded in 24-well dishes and continued to be cultured until confluent. After that, after 24 hours of culture in serum-free (FBS-free) Dulbecco's modified Eagle medium (DMEM), a single width wound was made on the culture bottom, and 0.3% FBS-containing DMEM (control) or 0.3% FBS-containing DMEM + BPU17 (1, 3, or 5 μM) was added and cultured for 18 hours. BPU17 was used, which was kindly provided by Professor Bunta Watanabe of Kyoto University. After 18 hours, the width of the wound on the culture bottom was measured to quantitatively evaluate the amount of cell migration. The results of measuring the width of the wound on each culture bottom are shown in Figure 1. In the figure, 0.3% FBS-containing DMEM (control) is represented as 0.3% FBS, 0.3% FBS+BPU17 1μM, 0.3% FBS+BPU17 3μM, and 0.3% FBS+BPU17 5μM are represented as 0.3% FBS, 0.3% FBS+BPU17 1μM, 0.3% FBS+BPU17 3μM, and 0.3% FBS+BPU17 5μM, respectively, and the vertical axis is the width of the wound on the culture bottom (μm). Figure 2 shows photographs of the culture bottom after 0 hours or 18 hours of culture when 0.3% FBS-containing DMEM (control) or 0.3% FBS+BPU17 3μM was added. As shown in Figures 1 and 2, it was revealed that the addition of BPU17 concentration-dependently suppressed the migration of retinal pigment epithelial cells, which is one of the biological characteristics of epithelial to mesenchymal transition (EMT).

[0050] [Example 2] In the same culture system as in Example 1, RPE-1 cells were treated with DMEM (None), 0.3% FBS, or 0.3% FBS + BPU17 3μM, and after 18 hours, the cells were formalin fixed and stained with alpha smooth muscle actin (α-SMA) and nuclei with anti-α-SMA antibody and DAPI, respectively. Next, the cells were stimulated with DMEM (none), transforming growth factor-β2 (TGF-β2), a cytokine that promotes fibrosis, or TGF-β2 + BPU17 3μM, after which the cell extract was collected and immunoblotted using anti-α-SMA antibody. The results of observing the cells with a fluorescent microscope after collecting the cell extract are shown in Figure 3, and the results of the immunoblot are shown in Figure 4.

[0051] As shown in Figures 3 and 4, in the absence of BPU17, stimulation with TGF-β2 increased the expression of α-SMA, which promotes fibrosis, but treatment with BPU17 suppressed the expression of α-SMA. Therefore, when considered together with the results of Example 1 above, treatment with BPU17 is thought to suppress epithelial-mesenchymal transition (EMT) of retinal pigment epithelial cells, leading to the suppression of fibrotic scar formation in the retina.

[0052] [Example 3] Based on the results of Example 2, a mouse subretinal scar formation model was used to examine whether BPU17 has an inhibitory effect on subretinal fibrous scar formation. A mouse subretinal scar model was prepared according to the method of Kobayashi et al. (Investigative ophthalmology & visual science, Volume 60, Issue 2 (2019)) as follows. Specifically, the retina of an 8-week-old mouse (CL57BL / 6 female: SLC) was irradiated with a laser (200 mW, 75 μm, 0.1 seconds, 532 nm), and photocoagulation was performed around the optic nerve, specifically about 4 locations within 2 to 3 papilla diameters around the disc. At the same time, a control without BPU17 (0.3% FBS) and 0.3% FBS + BPU17 (30, 100, 300 μM) were injected into the eye. After 7 days, a control without BPU17 and 0.3% FBS + BPU17 (30, 100, 300 μM) were injected into the eye again. On the 21st day, the eyeballs were enucleated and fixed, and then type I collagen was stained with a primary collagen antibody and observed under a microscope while measuring the area of ​​fibrosis. The results of the observation under a microscope are shown in FIG. 5, and the results of the measurement of the area of ​​fibrosis are shown in FIG. 6. The vertical axis in FIG. 6 represents the area of ​​fibrosis (μm 2 ).

[0053] As shown in Figures 5 and 6, administration of BPU17 inhibited type I collagen-induced fibrosis in a concentration-dependent manner, confirming that BPU17 inhibits retinal fibrosis in vivo as well.

[0054] [Example 4] Human aortic endothelial cells (HAoEC) were cultured and cell proliferation was evaluated by incorporation of bromodeoxyuridine (BrdU). HAoEC were seeded on a 12-well plate dish (COLI-film 14 mm coverslip: 1 mL HEC-C1 medium / well), and 0.5 hours later, the medium (1 mL HEC-C1) was replaced for each well. The next day, the medium was replaced for each well with either (1) HEC-C1 medium alone, (2) HEC-C1 medium + BPU17 1 μM, (3) HEC-C1 medium + BPU17 3 μM, or (4) HEC-C1 medium + BPU17 10 μM. After 4.5 hours, BrdU (final concentration 100 μM: BruU 25 mM 4 μl / well) was added.

[0055] The next day, the sections were fixed with 4% paraformaldehyde (PFA) + 4% sucrose in ×1 PBS(-) (20 h BrdU incubation). Wash 4 times with PBS(-) ×1 ·PBS(-)+0.1% Triton X-100 Incubate at room temperature for 15 minutes Wash 4 times with PBS(-) ×1 1N HCl Incubate on ice for 10 minutes 2N HCl 10 min at room temperature Wash 4 times with PBS(-) ×1 0.1 M boric acid pH 8.5, 5 min incubation at room temperature, 2 times Wash 4 times with PBS(-) ×1 Block for 45 minutes at 37℃ BrdU-Ab (Dako M0744) 1 / 100 dilution, 1.5 hours at 37℃ Wash 4 times with PBS(-) ×1 Alexa® 568-labeled mouse antibody, diluted 1 / 500, 1 hour at 37°C Wash 4 times with PBS(-) ×1 Hoechst® 2μg / ml 5 minutes at room temperature Observed under a microscope at ×100

[0056] The results are shown in Figure 7. As is clear from Figure 7, it was revealed that BPU17 inhibits BrdU incorporation into aortic vascular endothelial cells in a concentration-dependent manner. In other words, it can be said that BPU17 can inhibit the proliferation of vascular endothelial cells.

[0057] [Example 5] HAoECs were cultured in Matrigel, and tube formation, an indicator of angiogenesis, was examined by the following method. First, 1.25 mL / 2 mL tubes of Matrigel solution were prepared in a 24-well plate (stored at -20°C until use) coated with Matrigel (registered trademark: (Becton Dickinson)). The following Matrigel solutions (300 μL / well) were then added to the 24-well plate (3 wells / sample) and incubated at 37°C for 1 hour. (1) Control (dimethyl sulfoxide: DMSO) (2)DMSO+BPU17 1μM(1mM 1.25μL) (3)DMSO+BPU17 3μM(10mM 0.375μL) (4)DMSO+BPU17 10μM(10mM 1.25μL)

[0058] Next, HAoEC (passage 7: P7) suspension (2 × 10 4 HEC-C1 cells / 1 mL) were inoculated onto Matrigel with any of the following (5) to (8) at a concentration of 1 ml / well. (5) Control (DMSO) 3 mL HEC-C1 (6)DMSO+BPU17 1μM (1 mM 3 μL / 3 mL HEC-C1) (7)DMSO+BPU17 3μM(10mM 0.9μL / 3mL HEC-C1) (8)DMSO+BPU17 10μM(10mM 3μL / 3mL HEC-C1)

[0059] Photographs taken under a microscope (×40) 22 hours after inoculation are shown in FIG. 8, the proportion (%) of branching points per cell number is shown in FIG. 9A, and the lumen length (μm) is shown in FIG. 9B. As is clear from FIG. 8, FIG. 9A, and FIG. 9B, it was revealed that the addition of BPU17 inhibited lumen formation. Therefore, when examined together with the results of Example 4, it was shown that BPU17 can suppress angiogenesis.

[0060] [Example 6] Based on the results of Example 5, a mouse retinal choroidal neovascularization (CNV) model was used to examine whether BPU17 has an inhibitory effect on CNV formation. A mouse CNV model was created according to the method of Ishikawa et al. (Exp Eye Res. 2016; 142:19-25) as follows. Specifically, the retina of an 8-week-old mouse (CL57BL / 6 female: SLC) was irradiated with a laser (200 mW, 75 μm, 0.1 seconds, 532 nm), and photocoagulation was performed around the optic nerve, specifically about 4 locations 2 to 3 papilla diameters around the disc. At the same time, 0.3% FBS + BPU17 (30, 100 μM) was injected into the eye. On the 7th day, the eyeball was removed and fixed, and then incubated with Alexa Fluor 488-conjugated isolectin (Isolectin) GS-IB4 for 24 hours and diluted 1:100 in PBS. The preparations were finally washed with PBS, mounted with 50% glycerol in PBS, and examined under a BZ-X710 fluorescence microscope (Keyence). The area of ​​CNV was measured using NIH ImageJ software. As a control without BPU17, PBS was injected into the eye on day 0. The microscopic observation results are shown in Figure 10, and the measurement results of the CNV area are shown in Figure 11. The vertical axis in Figure 10 represents the fibrosis area (μm 2 ).

[0061] 10 and 11, administration of BPU17 suppressed CMV in a concentration-dependent manner, thus confirming that BPU17 suppresses angiogenesis in the retina and choroid through in vivo testing as well.

[0062] [Example 7] Next, the EMT inhibitory effect of BPU17 was examined using EMT markers. Human alveolar epithelial cell line A549 or human hepatic stellate cell line LI90 were cultured for 24 hours in the above-mentioned tissue-free DMEM medium. Then, TGFβ-2 1ng / mL only, or TGFβ-2 1ng / mL and BPU17 3μM were added and cultured for another 18 hours. Then, the cells were collected, total RNA was extracted using Rneasy Mini Kit (Qiagen), cDNA was synthesized, and qPCR was performed using SYBR Green reagents and a StepOnePlus Real Time PCR System (Applied Biosystems) to measure the expression level of connective tissue growth factor (CTGF) mRNA, a fibrosis-related molecule. Similarly, human hepatic stellate cell line LI90 was cultured for 24 hours in the above-mentioned tissue-free DMEM medium. Then, TGFβ-2 1ng / mL only, no TGFβ, or TGFβ-2 1ng / mL and BPU17 3μM were added and cultured for another 18 hours. The cells were then harvested, total RNA was extracted in the same manner as above, and cDNA was synthesized and then qPCR was performed to measure the expression level of α-smooth muscle actin (αSM-actin) mRNA, a fibrosis-related molecule. The results are shown in Figures 12 and 13.

[0063] As is clear from Figures 12 and 13, it was revealed that BPU17 suppresses the expression of CTGF in cells derived from alveolar epithelium and αSM-actin in hepatic stellate cells. Therefore, it was confirmed that BPU17 may have an anti-fibrotic effect not only in the retina but also in the lung and liver. [Industrial Applicability]

[0064] The pharmaceutical composition of the present invention can be used for the prevention or treatment of angiogenesis-related diseases. In particular, by strongly suppressing retinal-choroidal neovascularization by vascular endothelial cells in the retina-choroidal membrane or fibrous scar formation in retinal pigment epithelial tissue, the pharmaceutical composition can be used as a prophylactic or therapeutic agent for retinal-choroidal disorders such as diabetic retinopathy, age-related macular degeneration, retinal detachment, proliferative vitreoretinopathy, uveitis, eye infection, retinopathy of prematurity, neovascular maculopathy, and retinal-choroiditis.

Claims

1. A pharmaceutical composition for use in the prevention or treatment of angiogenesis-related diseases, comprising 1-(cyclobutylcarbonyl)-3-(4-chlorophenyl)urea or a pharmacologically acceptable salt thereof as an active ingredient.

2. 2. The pharmaceutical composition according to claim 1, wherein the angiogenesis-associated disease is an ocular angiogenesis-associated disease.

3. The pharmaceutical composition according to claim 2, wherein the ocular angiogenesis-related disease is a retinal-choroidal disorder, a keratoconjunctival disorder, or a neovascular glaucoma.

4. 4. The pharmaceutical composition according to claim 3, wherein the retinal and choroidal disorders are diabetic retinopathy, age-related macular degeneration, retinal detachment, proliferative vitreoretinopathy, uveitis, eye infection, retinopathy of prematurity, neovascular maculopathy, or retinal and choroiditis.

5. The pharmaceutical composition according to claim 2, characterized in that the ocular angiogenesis-related disease is the formation or contraction of fibrous scars caused by any one of retinal-choroidal disorders, keratoconjunctival disorders, and neovascular glaucoma.

6. The pharmaceutical composition according to claim 5, characterized in that the fibrotic scar is a epiretinal, intraretinal and / or subretinal fibrotic scar.

7. The pharmaceutical composition according to claim 6, wherein the fibrous scar is a fibrous scar in the retinal pigment epithelium tissue under the retina.

8. The pharmaceutical composition according to claim 2, wherein the angiogenesis-related disease is organ fibrosis.

9. The pharmaceutical composition according to claim 8, wherein the organ fibrosis is pulmonary fibrosis or liver fibrosis.

10. The pharmaceutical composition according to claim 1, which is used for inhibiting angiogenesis.

11. The pharmaceutical composition according to claim 10, characterized in that the angiogenesis is ocular angiogenesis.

12. The pharmaceutical composition according to claim 11, characterized in that the neovascularization is epiretinal, intraretinal and / or subretinal neovascularization.

Citation Information

Patent Citations

  • Methine compound and silver halide photosensitive material for photography containing the compound

    JP2001323180A

  • Compositions and methods for modulating C-KIT and PDGFR receptors

    JP2010506948A

  • Inhibitor for retinochoroidal disorders

    WO2014188716A1